Faculty

Beatriz M. Carreno, PhD

Research Professor of Pathology and Laboratory Medicine

Department: Pathology and Laboratory Medicine

Graduate Group Affiliations

Contact information

PCAM South Tower, 8th Floor
3400 Civic Blvd
Philadelphia, PA 19104

Office: 215-573-7044
Lab: 215-573-4931

Email:
bcarreno@upenn.edu

Publications

Search PubMed for articles

Education:
BS
Universidad Simon Bolivar, Caracas, Venezuela, 1981.
PhD (Microbiology)
Georgetown University School of Medicine, 1989.

Links
Search PubMed for articles
University of Pennsylvania, Center for Cellular Immunotherapies site

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

Benton A., Liu J., Poussin M.A., Lang Goldgewicht A., Udawela M., Bear A.S., Wellhausen N., Carreno B.M., Smith P.M., Beasley M.D., Kiefel B.R., Powell D.J. Jr: Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy. Cancer Cell 43(7): 1365-1376.e5, Jul 2025 Notes: doi: 10.1016/j.ccell.2025.05.006. Epub 2025 Jun 5. PMID: 40480232

Blanchard T., Faridi P., Xu C., Bear A.S., Rasool R.U., Huang G., Lim T.C.C., Ayala R., Gabunia K., Ji M., Posey A.D. Jr, Scholler J., Asangani I.A., Purcell A.W., Linette G.P., June C.H., Carreno B.M.: LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma. Sci Rep 15(1): 13007, Apr 2025 Notes: doi: 10.1038/s41598-025-96877-9. PMID: 40234527 Free PMC article.

Porazzi P., Nason S., Yang Z., Carturan A., Ghilardi G., Guruprasad P., Patel R.P., Tan M., Padmanabhan A.A., Lemoine J., Fardella E., Zhang Y., Pajarillo R., Chen L., Ugwuanyi O., Markowitz K., Delman D., Angelos M.G., Shestova O., Isshiki Y., Blanchard T., Béguelin W., Melnick A.M., Linette G.P., Beatty G.L., Carreno B.M., Cohen I.J., Paruzzo L., Schuster S.J., Ruella M.: EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell 43(3): 537-551.e7, Mar 2025 Notes: doi: 10.1016/j.ccell.2025.01.013. Epub 2025 Feb 20. PMID: 39983725

Bear A.S., Nadler R.B., O'Hara M.H., Stanton K.L., Xu C., Saporito R.J., Rech A.J., Baroja M.L., Blanchard T., Elliott M.H., Ford M.J., Jones R., Patel S., Brennan A., O'Neil Z., Powell D.J. Jr, Vonderheide R.H., Linette G.P., Carreno B.M.: Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. J Clin Invest 134(21): e175790, Sep 2024 Notes: doi: 10.1172/JCI175790. PMID: 39287991 Free PMC article. Clinical Trial.

Patel, R.P., Ghilardi, G., Zhang, Y., Chiang, Y., Xie, W., Guruprasad, P., Kim, K., Chun, I., Angelos, M.G., Pajarillo, R., Hong, S., Lee, Y., Shestova, O., Shaw, C., Cohen, I., Gupta, A., Vu, T., Qian, D., Yang, S., Nimmagadda, A., Snook, A.E., Siciliano, N., Rotolo, A., Inamdar, A., Harris, J., Ugwuanyi, O., Wang, M., Carturan, A., Paruzzo, L., Chen, L., Ballard, H.J., Blanchard, T., Xu, C., Abdel-Mohsen, M., Gabunia, K., Wysocka, M., Linette, G.P., Carreno, B.M., Barrett, D.M., Teachey, D.T., Posey, A.D., Powell Jr., D.J., Sauter, C.T., Pileri, S., Pillai, V., Scholler, J., Rook, A.H., Schuster, S.J., Barta, S.K., Porazzi, P., Ruella, M.: CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Sci Immunol 9(97): eadn6509, Jul 2024.

Patel R.P., Ghilardi G., Zhang Y., Chiang Y.H., Xie W., Guruprasad P., Kim K.H., Chun I., Angelos M.G., Pajarillo R., Hong S.J., Lee Y.G., Shestova O., Shaw C., Cohen I., Gupta A., Vu T., Qian D., Yang S., Nimmagadda A., Snook A.E., Siciliano N., Rotolo A., Inamdar A., Harris J., Ugwuanyi O., Wang M., Carturan A., Paruzzo L., Chen L., Ballard H.J., Blanchard T., Xu C., Abdel-Mohsen M., Gabunia K., Wysocka M., Linette G.P., Carreno B.M., Barrett D.M., Teachey D.T., Posey A.D., Powell D.J. Jr, Sauter C.T., Pileri S., Pillai V., Scholler J., Rook A.H., Schuster S.J., Barta S.K., Porazzi P., Ruella M.: CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Sci Immunol 9(97): eadn6509, Jul 2024 Notes: doi: 10.1126/sciimmunol.adn6509. Epub 2024 Jul 19. PMID: 39028827 Free PMC article.

Linette GP, Bear AS, Carreno BM: Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations. Clin Cancer Res Jan 2024 Notes: doi: 10.1158/1078-0432.CCR-23-1212. Online ahead of print.

Lee IK, Sharma N, Noguera-Ortega E, Liousia M, Baroja ML, Etersque JM, Pham J, Sarkar S, Carreno BM, Linette GP, Puré E, Albelda SM, Sellmyer MA.: A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy. Mol Ther 31(12): 3564-3578, Dec 2023.

Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA.: Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy. Blood Cancer Discov 4(2): 118-133, Mar 2023.

Bear, A.S., Nadler, R.B., Scholler, J., Vonderheide, R.H., Linette, G.P., Carreno, B.M.: TCR1020 specific for KRAS G12V restricted to HLA-A*11:01 exhibits potent and precise antigen specificity for clinical development. AACR- Targeting Ras, Philadelphia, PA Mar 2023 Notes: Oral Presentation.